Total Funding
64
21
Total FundingVenture - Series Unknown raised
Growth Score
0 pts
Heat Score
1 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
337384
Prolong Pharmaceuticals develops and markets biopharmaceutical products for the treatment of various diseases.
About the Company
Prolong Pharmaceuticals, Inc. develops and markets biopharmaceutical products. Its products include PEG-uricase for the treatment of hyperuricemia; PEG-arginase for the treatment of melanoma and hepatocellular carcinoma; PEG-protein for the treatment of hypovolemic shock; PEG-peptide antibiotic to treat staphylococcus infections; PEG-streptokinase
for myocardial infarcts; anti-cancer agents; and Erythropoietin, a biopharmaceutical that provides a solution for anemia. The company also offers custom manufacturing services; and licenses its products to pharmaceutical companies. Prolong Pharmaceuticals, Inc. was founded in 2002 and is based in New Jersey.
